Logo-jrip
Submitted: 08 Apr 2020
Accepted: 08 Jun 2020
ePublished: 26 Jul 2020
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Renal Inj Prev. 2021;10(1): e03.
doi: 10.34172/jrip.2021.03
  Abstract View: 84
  PDF Download: 36

Original

Effect of allopurinol on diabetic nephropathy; a double-blind clinical trial study

Saeed Mardani 1 ORCID logo, Farzaneh Kadkhodaei-Elyaderani 1 * , Ali Momeni 1, Maryam Saeedi 1

1 Department of Internal Medicine, School of Medicine, Shahrekord University of Medical Sciences, Isfahan, Iran
*Corresponding author: Farzaneh Kadkhodaei-Elyaderani, Email: farzanehmedical@gmail.com

Abstract

Introduction: Diabetic nephropathy (diabetic kidney disease) is the most common cause of renal failure.

Objectives: Regarding the role of allopurinol in the improvement of diabetic kidney disease, this study aimed to investigate the ameliorative effect of allopurinol in diabetic nephropathy patients.

Patients and Methods: This double-blind clinical trial study was performed on 60 patients with diabetic kidney disease referenced to nephrology clinic during 2019-2020. Patients were divided into case (treated with allopurinol 100 mg/d) and control (received placebo pill) groups. Three and six months of intervention, complete blood count (CBC), fasting blood sugar levels (FBS), serum blood urea nitrogen (BUN) levels, creatinine (Cr) and uric acid (UA) levels, 24 hours urinary protein, glomerular filtration rate (GFR), neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) were measured and compared between the two groups.

Results: After six months, reduction of UA and 24 hours urinary protein were not significant in the control group (P > 0.05) but it was significant in the allopurinol group (P < 0.05). In the allopurinol group, NLR and PLR levels decreased significantly during the six months (P < 0.01) however there was no significant change in the control group (P > 0.05).

Conclusion: Low dosage of allopurinol (100 mg/d) reduces UA, proteinuria, NLR and PLR in patients after six months. Therefore it can be used for diabetic nephropathy patients as a supplementary, inexpensive and safe treatment.

Keywords: Diabetic nephropathy, Allopurinol, Uric acid, Diabetic kidney disease

Implication for health policy/practice/research/medical education:

In this study, 60 patients with diabetic kidney disease divided into two groups. Patients in the intervention group were treated with allopurinol pill and patients in the control group received placebo pill. The results of this study showed that allopurinol can play a significant role in reducing uric acid and 24-hour urine protein levels without significant changes in the patients’ blood factors.

Please cite this paper as: Mardani S,. Effect of allopurinol on diabetic nephropathy; a double-blind clinical trial study. J Renal Inj Prev. 2021; 10(1): e03. doi: 10.34172/jrip.2021.03.

First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 84

Your browser does not support the canvas element.


PDF Download: 36

Your browser does not support the canvas element.